"The only issue is the cost
of treatment generally associated with these therapies is hundreds of thousands
or even millions of dollars per patient per year, which no plan can
realistically be prepared for."
— Mesfin
Tegenu, R.Ph., president of Philadelphia-based PBM PerformRx, talked with AIS's
RADAR on Drug Benefits
about AveXis' launch of Zolgensma, the wave of new gene therapies in
development, and how PBMs will handle their unprecedented high costs.
No comments:
Post a Comment